Skip to main content

Search

Our Commitment to Transparency

Transparency of Innovation and Collaboration

The patients and healthcare professionals who rely on our products place their trust in the reliability of our clinical research, the rigor of our scientific publications, the independence of medical education we fund and the integrity of our professional relationships.

Our approach to product development and peer-to-peer education is focused on improving the health of patients and driving improved clinical outcomes through transparent, compliant activities. Healthcare providers with real-world clinical experience in specific therapeutic areas are uniquely qualified to provide education and insights into new advancements regarding Johnson & Johnson products.

Science sometimes advances quickly, and peer-to-peer education can address potential treatment gaps as it allows providers to objectively discuss important medical information with expert colleagues regarding the appropriate use of our products.

We also collaborate with leading physicians on the development of new surgical devices, medicines and diagnostics. These activities lead to important medical advances that have the potential to improve patients’ lives.

Our companies are governed by the following standards and other legal and voluntary requirements:

  • Physician payment transparency reporting requirements, including the United States Open Payments program.
  • United States and international laws and regulations and industry standards governing registration and reporting of clinical trial results.
  • Standards published by the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents research-based pharmaceutical and biotechnology companies, and the Advanced Medical Technology Association (AdvaMed), which represents medical device manufacturers. These associations and similar industry organizations outside of the United States have established codes of ethics intended to protect medical decision-making from improper financial incentives.
  • In our corporate social responsibility reporting, we include numerous metrics associated with the Global Reporting Initiative (GRI), which allows our business leaders to target improvement efforts in key areas.
  • Partnerships are central to all that we do. Beyond our research and development partnerships, we recognize the importance of building multi-sector alliances to address critical health needs. We are committed to working across sectors with governments, donors, non-governmental organizations (NGOs), multilateral organizations, and other stakeholders. Together, we foster innovative approaches and increase access to new medicines and new technological solutions. We set a strong foundation for partnerships, which may include licensing agreements guided by terms that address public health needs, and we aim to mindfully reflect our commitment to a pro-access legal environment. For example, going forward, our contracts will strive to incorporate a number of pro-access terms identified by the Access to Medicines Foundation in the 2014 Access to Medicine Index.